Changeflow GovPing Government & Legislation DEA Reschedules FDA-Approved Marijuana Products...
Priority review Rule Amended Final

DEA Reschedules FDA-Approved Marijuana Products From Schedule I to Schedule III

Favicon for www.federalregister.gov US Federal Register — Public Inspection Desk
Published
Detected
Email

Summary

The DEA has published a direct final rule rescheduling FDA-approved products containing marijuana from Schedule I to Schedule III of the Controlled Substances Act, with a corresponding change to permit requirements. The rule is scheduled for official publication on April 28, 2026, and represents a significant regulatory shift in how certain marijuana-derived pharmaceutical products are classified under federal law. This change will affect manufacturers, healthcare providers, and patients who handle or use these specific FDA-approved controlled substance products.

“Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements”

DEA , verbatim from source
Published by DEA on federalregister.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors US Federal Register — Public Inspection Desk for new government & legislation regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 38 changes logged to date.

What changed

The DEA has issued a direct final rule that reclassifies FDA-approved products containing marijuana from Schedule I to Schedule III of the Controlled Substances Act. This action removes these products from the most restrictive controlled substance category, reflecting a determination that they have accepted medical use and accepted safety for use under medical supervision. The rule also modifies associated permit requirements for handling these substances.

Pharmaceutical manufacturers producing FDA-approved marijuana-containing products, healthcare providers who prescribe or dispense these medications, and facilities that handle these controlled substances will need to update their DEA registration status, inventory procedures, and security requirements to reflect the Schedule III classification. Schedule III substances carry different recordkeeping, reporting, and physical security standards than Schedule I substances.

Archived snapshot

Apr 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Public Inspection :: Rule

Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements

An unpublished Rule
by the Drug Enforcement Administration on 04/28/2026

  • Document Details
  • Sharing Public Inspection Document This document is unpublished. It is scheduled to be published on 04/28/2026.

Once it is published it will be available on this page in an official form.
Until then, you can download the unpublished PDF version.

Although we make a concerted effort to reproduce the original document
in full on our Public Inspection pages, in some cases graphics may not
be displayed, and non-substantive markup language may appear alongside
substantive text. If you are using public inspection listings for legal
research, you should verify the contents of documents against a final,
official edition of the Federal Register. Only official editions of the Federal Register provide legal
notice of publication to the public and judicial notice to the courts under 44 U.S.C. 1503 & 1507.
Learn more here.

Public Inspection Document

Get daily alerts for US Federal Register — Public Inspection Desk

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from DEA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
DEA
Published
April 28th, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
2026-08176

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug scheduling compliance Controlled substance handling Permit requirements
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Topics
Healthcare Anti-Money Laundering

Get alerts for this source

We'll email you when US Federal Register — Public Inspection Desk publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!